NASDAQ:CCXI - ChemoCentryx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$11.30 +0.24 (+2.17 %)
(As of 10/23/2018 03:13 PM ET)
Previous Close$11.06
Today's Range$10.77 - $11.34
52-Week Range$5.42 - $15.08
Volume4,296 shs
Average Volume336,481 shs
Market Capitalization$574.04 million
P/E Ratio31.47
Dividend YieldN/A
Beta1.55
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
Previous Symbol
CUSIP16383L10
Phone650-210-2900

Debt

Debt-to-Equity Ratio0.51
Current Ratio2.69
Quick Ratio2.69

Price-To-Earnings

Trailing P/E Ratio31.47
Forward P/E Ratio-13.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$82.50 million
Price / Sales6.89
Cash Flow$0.3710 per share
Price / Cash30.46
Book Value$1.63 per share
Price / Book6.93

Profitability

EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net Margins18.69%
Return on Equity39.31%
Return on Assets9.53%

Miscellaneous

Employees66
Outstanding Shares50,310,000
Market Cap$574.04 million
OptionableN/A

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) released its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $15.02 million for the quarter, compared to analysts' expectations of $16.88 million. ChemoCentryx had a net margin of 18.69% and a return on equity of 39.31%. View ChemoCentryx's Earnings History.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for ChemoCentryx.

What price target have analysts set for CCXI?

6 Wall Street analysts have issued 1-year target prices for ChemoCentryx's shares. Their forecasts range from $12.50 to $20.00. On average, they anticipate ChemoCentryx's stock price to reach $16.70 in the next twelve months. This suggests a possible upside of 47.8% from the stock's current price. View Analyst Price Targets for ChemoCentryx.

What is the consensus analysts' recommendation for ChemoCentryx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 3 hold ratings, 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

What are Wall Street analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:
  • 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year end 2018 net cash of $2.49/ share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (8/13/2018)
  • 2. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (7/16/2018)

Who are some of ChemoCentryx's key competitors?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
  • Dr. Rajinder Singh, Sr. VP of Research (Age 51)
  • Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)
  • Dr. Markus J. Cappel, Chief Bus. Officer & Treasurer (Age 57)

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.26%) and Strs Ohio (0.10%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

Which institutional investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Plc Glaxosmithkline, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.

Which institutional investors are buying ChemoCentryx stock?

CCXI stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can. View Insider Buying and Selling for ChemoCentryx.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $11.30.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $574.04 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is http://www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]


MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  347
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel